R. Mass
- Oncology top 1%
- HER2/EGFR in Cancer Research 13
- Colorectal Cancer Treatments and Studies 12
- Cancer Treatment and Pharmacology 12
- Lung Cancer Research Studies 7
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 5
-
- Lung Cancer Treatments and Mutations 6
- Gastric Cancer Management and Outcomes 5
- Cancer Research top 5%
-
- Monoclonal and Polyclonal Antibodies Research 7
- Co-authors
- Fairooz F. KabbinavarSomnath SarkarHerbert I. HurwitzJulie HambletonEmily K. BergslandWilliam NovotnyB. NelsonJohn Hamm
- Journals
- Journal of Clinical Oncology (20 papers)European Journal of Cancer (5 papers)Hypertension (2 papers)
- Partner nations
- United StatesFranceAustria
In The Last Decade
R. Mass
41 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 2.5k
- Hepatology 498
- Pulmonary and Respiratory Medicine 1.2k
- Cancer Research 503
- Radiology, Nuclear Medicine and Imaging 594
Countries citing papers authored by R. Mass
This map shows the geographic impact of R. Mass's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Mass with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Mass more than expected).
Fields of papers citing papers by R. Mass
This network shows the impact of papers produced by R. Mass. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Mass. The network helps show where R. Mass may publish in the future.
Co-authorship network
The 25 scholars most cited alongside R. Mass, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 3 | |
| 2 | Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trialbreakdown → | 2005 | 709 |
| 3 | 2005 | 259 | |
| 4 | 2005 | 137 | |
| 5 | 2005 | 40 | |
| 6 | 2005 | 7 | |
| 7 | 2004 | 87 | |
| 8 | 2004 | 40 | |
| 9 | 2004 | 11 | |
| 10 | 2003 | 14 | |
| 11 | 2003 | 2 | |
| 12 | 2003 | 99 | |
| 13 | 2002 | 46 | |
| 14 | 2002 | 28 | |
| 15 | Estrogen receptor status in the Herceptin (trastuzumab) clinical trials: Incidence and relation to clinical benefit | 2001 | 2 |
| 16 | 2001 | 134 | |
| 17 | 2001 | 4 | |
| 18 | 1989 | 43 | |
| 19 | 1979 | 46 | |
| 20 | 1979 | 50 |
About R. Mass
R. Mass is a scholar working on Oncology, Hepatology, Internal Medicine, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine, having authored 43 papers that have together received 3.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (13 papers), Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (12 papers), Lung Cancer Research Studies (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Lung Cancer Treatments and Mutations (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Gastric Cancer Management and Outcomes (5 papers). The work is most often cited by research in Oncology (2.5k citations), Hepatology (498 citations), Pulmonary and Respiratory Medicine (1.2k citations), Cancer Research (503 citations) and Radiology, Nuclear Medicine and Imaging (594 citations). R. Mass has collaborated with scholars based in United States, France and Austria. Frequent co-authors include Fairooz F. Kabbinavar, Somnath Sarkar, Herbert I. Hurwitz, Julie Hambleton, Emily K. Bergsland, William Novotny, B. Nelson, John Hamm, Michael McCleod and Taral Patel. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Hypertension, Lung Cancer and Breast Cancer Research and Treatment.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.